【摘要】 目的分析联合使用酪酸梭菌活菌与匹维溴铵治疗腹泻型肠易激综合征的临床疗效。方法以66例腹泻型肠易激综合征为研究对象,均为我院在2018年5月至2019年5月之间收治,随机将其分为对照组33例与观察组33例,对照组患者口服匹维溴铵片治疗,观察组患者在对照组基础上加服酪酸梭菌活菌散治疗,治疗后记录两组疗效,观察其不良反应发生率。结果对比两组患者治疗总有效率,观察组93.9%明显高于对照组66.7%,组间数据对比有显著差异,P<0.05。对比两组患者不良反应发生率,观察组9.1%虽低于对照组18.2%,但是两组数据对比无明显差异,P>0.05。结论与单独使用匹维溴铵相比,联合使用匹维溴铵与酪酸梭菌活菌治疗腹泻型肠易激综合征的临床疗效更好,可见联合治疗方案用于治疗腹泻型肠易激综合征疗效确切,安全可靠,建议在临床上推广应用该治疗方案。更多还原

【Abstract】 Objective to analyze clinical curative effect of clostridium butyricum combined with pivobromide in treatment of diarrhea-predominant irritable bowel syndrome. Methods treat 66 cases diarrhea-predominant irritable bowel syndrome patients treated in our hospital from May 2018 to May 2019 as study objects. Divide them into control group(33 cases) and observation group(33 cases) randomly. Patients in control group were treated with pivebromide tablets orally, and patients in observation group with clostridium butyrate live bacteria powder on the basis of control group. Observe curative effect and adverse reactions incidence of two groups. Results total effective rate was 93.9% in observation group, significantly higher than 66.7% in control group. Data showed significant difference between two groups(P<0.05). Comparing incidence of adverse reactions between two groups, 9.1% in observation group was lower than 18.2% in control group, there was no significant difference between two groups, P>0.05. Conclusion compared with pivobromide, combination of pivobromide and clostridium butyricum has better clinical effect in treatment of diarrhea-predominant irritable bowel syndrome, with accurate curative effect, being safe and reliable in treatment of diarrhea-predominant irritable bowel syndrome. It is recommended to promote and apply the therapy in clinical practice.更多还原